These results suggest the potential utility of LMH-2 in the treatment of diabetic neuropathy and highlight a key role for TRPV1 in LMH-2’s antiallodynic mechanism, along with a possible, albeit limited, interaction with the MOR/NMDA complex. This evidence concerns the gene OPRM1 and diabetic neuropathy.